Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab and Pola-R-Mini-CHP in Elderly/Unfit Untreated DLBCL
NCT07714421Phase 1Not yet recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), high grade B-cell lymphoma (HGBCL) and 2 more, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Progression Free Survival up to 6 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)high grade B-cell lymphoma (HGBCL)primary mediastinal large B-cell lymphoma (PMBCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07714421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714421.